Gilead Donates Remdesivir to Aid Ethiopia’s Marburg Virus Response

1,200 Vials of Remdesivir Delivered to Aid Emergency Efforts

Foster City, Calif., December 3, 2025 – Gilead Sciences has provided its antiviral therapy, remdesivir, to the Ministry of Health of Ethiopia to help combat the country’s first outbreak of Marburg Virus Disease (MVD). The contribution underscores Gilead’s commitment to global health and rapid action during public health crises.

“At Gilead, we believe access to life-saving medicines should not be limited by geography or circumstance,” said Anu Osinusi, Vice President of Clinical Research for Hepatitis, Respiratory and Emerging Viruses at Gilead Sciences. “Our donation of remdesivir reflects our responsibility to act quickly and decisively when global health emergencies arise.”

Marburg Virus Disease is a rare but severe hemorrhagic fever with high mortality rates, requiring swift intervention to prevent further spread. Gilead is working closely with the Ministry of Health of Ethiopia to provide remdesivir for emergency use. This collaboration aims to strengthen outbreak response and treat affected communities.

Remdesivir is being provided for the treatment of confirmed or suspected MVD in Ethiopia following the authorization for emergency use by the Ethiopian Food & Drug Authority (EFDA). Remdesivir is not approved for the treatment of Marburg Virus Disease, and its safety and efficacy for this use are not established. The donation is based on preclinical data for filoviruses and extensive clinical safety data from remdesivir’s use in COVID-19 treatment. Remdesivir, marketed as Veklury® (remdesivir) 100 mg for injection, is approved for COVID-19 in approximately 50 countries and has been made available to more than 14.5 million COVID-19 patients globally, including over 8 million in low- and middle-income countries through Gilead’s voluntary licensing program.

This donation builds on Gilead’s long-standing efforts to address infectious diseases worldwide, including partnerships with governments, NGOs, and global health organizations to improve preparedness and response capabilities. Over the past decade, remdesivir has been provided for emergency and compassionate use during filovirus outbreaks in Sub-Saharan Africa, including recent MVD outbreaks in Rwanda and Tanzania.

For more information about Gilead’s commitment to global health, visit Gilead.com.

U.S. Indication for Veklury

Veklury is indicated for the treatment of COVID-19 in adults and pediatric patients (birth to <18 years, weighing at least 1.5 kg) who are:

• Hospitalized, or
• Not hospitalized but have mild-to-moderate COVID-19 and are at high risk for progression to severe disease, including hospitalization or death

For more information, please see the U.S. full Prescribing Information available at www.gilead.com.

U.S. Important Safety Information for Veklury

Contraindication

Veklury is contraindicated in patients with a history of clinically significant hypersensitivity reactions to Veklury or any of its components.

Warnings and precautions

• Hypersensitivity including infusion-related and anaphylactic reactions: Hypersensitivity reactions have been observed during and following administration of VEKLURY. Slower infusion rates, with a maximum infusion time of up to 120 minutes, can be considered to potentially prevent signs and symptoms of hypersensitivity. Monitor patients during infusion and observe patients for at least one hour after infusion is complete for signs and symptoms of hypersensitivity as clinically appropriate. If signs and symptoms of a clinically significant hypersensitivity reaction occur, immediately discontinue administration of VEKLURY and initiate appropriate treatment.
• Increased risk of transaminase elevations: Transaminase elevations have been observed in healthy volunteers and in patients with COVID-19 who received Veklury; these elevations have also been reported as a clinical feature of COVID-19. Perform hepatic laboratory testing in all patients (see Dosage and administration). Consider discontinuing Veklury if ALT levels increase to >10x ULN. Discontinue Veklury if ALT elevation is accompanied by signs or symptoms of liver inflammation.
• Risk of reduced antiviral activity when coadministered with chloroquine phosphate or hydroxychloroquine sulfate: Coadministration of VEKLURY and chloroquine phosphate or hydroxychloroquine sulfate is not recommended based on data from cell culture experiments demonstrating a potential antagonistic effect of chloroquine on the intracellular metabolic activation and antiviral activity of VEKLURY.

Adverse reactions

• The most common adverse reactions (incidence greater than or equal to 5%, all grades) observed with treatment with VEKLURY are nausea, ALT increased, and AST increased.

Drug interactions

• Coadministration of VEKLURY and chloroquine phosphate or hydroxychloroquine sulfate is not recommended based on data from cell culture experiments demonstrating a potential antagonistic effect of chloroquine on the intracellular metabolic activation and antiviral activity of VEKLURY.
• Other Drug Interactions
  Based on drug interaction studies conducted with VEKLURY, no clinically significant drug interactions are expected with inducers of cytochrome P450 (CYP) 3A4 or inhibitors of Organic Anion Transporting Polypeptides (OATP) 1B1/1B3 and, P-glycoprotein (P-gp). Remdesivir is a weak inhibitor of CYP3A and does not inhibit OATP1B1/1B3.

Dosage and administration

• Administration:
  Veklury should be given in a healthcare setting where staff are prepared to manage severe allergic reactions, including anaphylaxis.
• Testing:
  All patients should have liver function tests and prothrombin time checked before starting Veklury and monitored as needed during treatment.
• Treatment Duration:
  • Hospitalized Patients:
    • Start treatment as soon as possible after diagnosis.
    • If on mechanical ventilation or ECMO: treat for 10 days.
    • If not on mechanical ventilation/ECMO: treat for 5 days; may extend up to 10 days if needed.
  • Non-Hospitalized Patients:
    • Start treatment as soon as possible and within 7 days of symptom onset.
    • For those at high risk of severe COVID-19: treat for 3 days.
• Renal Impairment:
  • No dosage adjustment of Veklury is recommended in patients with any degree of renal impairment, including patients on dialysis. Veklury may be administered without regard to the timing of dialysis.

Pregnancy and lactation

• Pregnancy: A pregnancy registry has been established for Veklury Available clinical trial data for Veklury in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes following second- and third- trimester exposure. There are insufficient data to evaluate the risk of Veklury exposure during the first trimester. Maternal and fetal risks are associated with untreated COVID-19 in pregnancy.
• Lactation: Veklury can pass into breast milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Veklury and any potential adverse effects on the breastfed child from Veklury or from an underlying maternal condition. Breastfeeding individuals with COVID-19 should follow practices according to clinical guidelines to avoid exposing the infant to COVID-19.

For more information, please see the U.S. full Prescribing Information available at www.gilead.com.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Forward-Looking Statements

This company statement includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including Gilead’s ability to effectively manage the supply and distribution of remdesivir; Gilead’s ability to initiate, progress or complete clinical trials within currently anticipated timelines or at all, and the possibility of unfavorable results from ongoing or additional clinical trials, including those involving  remdesivir; and any assumptions underlying any of the foregoing. These and other risks, uncertainties and factors are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, as filed with the U.S. Securities and Exchange Commission. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaims any intent to update any such forward-looking statements.

U.S. full Prescribing Information for Veklury is available at www.gilead.com.

Veklury, Gilead and the Gilead logo are registered trademarks of Gilead Sciences, Inc., or its related companies.

For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on X/Twitter (@Gilead Sciences) and LinkedIn (@Gilead-Sciences).